US 11,590,136

Application 17/704,180 · Granted Feb 28, 2023

Topical formulation for a jak inhibitor

Estimated expiration

May 20, 2031

4y 181d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
May 20, 2011
+ 20 years
May 20, 2031
PTA +0d
May 20, 2031
TD cap (US 11,219,624)
May 20, 2031
Final
May 20, 2031

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 25, 2022
Earliest effective filing
May 20, 2011
Issue date
February 28, 2023
PTA
0 days
Base expiry (before PTA)
May 20, 2031

May 20, 2011 + 20 years = May 20, 2031

  • Continuation of application 17/541,439, filed Dec 3, 2021, issued as US 12,622,908
  • Continuation of application 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
  • Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
  • Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
  • Continuation of application 14/714,820, filed May 18, 2015
  • Continuation of application 13/112,370, filed May 20, 2011
  • Continuation of application 13/112,370, filed May 20, 2011
  • Continuation of application 14/714,820, filed May 18, 2015
  • Continuation of application 13/112,370, filed May 20, 2011
  • Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
  • Continuation of application 14/714,820, filed May 18, 2015
  • Continuation of application 13/112,370, filed May 20, 2011
  • Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
  • Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
  • Continuation of application 14/714,820, filed May 18, 2015
  • Continuation of application 13/112,370, filed May 20, 2011
  • Continuation of application 16/948,408, filed Sep 17, 2020, issued as US 11,219,624
  • Continuation of application 16/947,735, filed Aug 14, 2020, issued as US 10,869,870
  • Divisional of application 16/566,625, filed Sep 10, 2019, issued as US 10,758,543
  • Continuation of application 14/714,820, filed May 18, 2015
  • Continuation of application 13/112,370, filed May 20, 2011
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term
  • PRO61/347,132 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to May 20, 2031 (earliest expiring referenced patent: US 11,219,624)

  • US 12,092,001· Application 18/355,334Capping patent

    Method for controlling an internal combustion engine including at least one exhaust-gas aftertreatment component having an electric heating element

    Filing date
    Jul 19, 2023
    Earliest effective filing
    Jul 19, 2023
    Issue date
    Sep 17, 2024
    PTA
    0 days
    Calculated expiration
    Jul 19, 2043

    Jul 19, 2023 + 20y = Jul 19, 2043

  • US 11,219,624· Application 16/948,408Capping patent

    Topical formulation for a jak inhibitor

    Filing date
    Sep 17, 2020
    Earliest effective filing
    May 20, 2011
    Issue date
    Jan 11, 2022
    PTA
    0 days
    Calculated expiration
    May 20, 2031

    Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    May 20, 2011 + 20y = May 20, 2031

  • US 10,869,870· Application 16/947,735

    Topical formulation for a jak inhibitor

    Filing date
    Aug 14, 2020
    Earliest effective filing
    May 20, 2011
    Issue date
    Dec 22, 2020
    PTA
    0 days
    Calculated expiration
    May 20, 2031

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    May 20, 2011 + 20y = May 20, 2031

  • US 10,758,543· Application 16/566,625

    Topical formulation for a jak inhibitor

    Filing date
    Sep 10, 2019
    Earliest effective filing
    May 20, 2011
    Issue date
    Sep 1, 2020
    PTA
    0 days
    Calculated expiration
    May 20, 2031

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 13/112,370, filed May 20, 2011

    May 20, 2011 + 20y = May 20, 2031

  • US 11,590,136· Application 17/704,180(from application 17/704,180)

    Topical formulation for a jak inhibitor

    Filing date
    Mar 25, 2022
    Earliest effective filing
    May 20, 2011
    Issue date
    Feb 28, 2023
    PTA
    0 days
    Calculated expiration
    May 20, 2031

    Continuation of 17/541,439, filed Dec 3, 2021, issued as US 12,622,908

    Continuation of 16/948,408, filed Sep 17, 2020, issued as US 11,219,624

    Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    Continuation of 16/948,408, filed Sep 17, 2020, issued as US 11,219,624

    Continuation of 16/947,735, filed Aug 14, 2020, issued as US 10,869,870

    Divisional of 16/566,625, filed Sep 10, 2019, issued as US 10,758,543

    Continuation of 14/714,820, filed May 18, 2015

    Continuation of 13/112,370, filed May 20, 2011

    May 20, 2011 + 20y = May 20, 2031

Notes (1)

  • [TD_REFS_TRUNCATED] Found 8 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/704,180 · US 11,590,136

PatentReply compiles the prosecution history behind US 11,590,136: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11590136

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.